Unknown

Dataset Information

0

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.


ABSTRACT: The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients with treatment-resistant major depression (TRD); these effects have been reported to last for 1 week in some patients. However, the extent and duration of this antidepressant effect over longer periods has not been well characterized under controlled conditions. Riluzole, a glutamatergic modulator with antidepressant and synaptic plasticity-enhancing effects, could conceivably be used to promote the antidepressant effects of ketamine. This study sought to determine the extent and time course of antidepressant improvement to a single-ketamine infusion over 4 weeks, comparing the addition of riluzole vs placebo after the infusion. Forty-two subjects (18-65) with TRD and a Montgomery-Asberg Depression Rating Scale (MADRS) score of ? 22 received a single intravenous infusion of ketamine (0.5?mg/kg). Four to six hours post-infusion, subjects were randomized to double-blind treatment with either riluzole (100-200?mg/day; n=21) or placebo (n=21) for 4 weeks. Depressive symptoms were rated daily. A significant improvement (P<0.001) in MADRS scores from baseline was found. The effect size of improvement with ketamine was initially large and remained moderate throughout the 28-day trial. Overall, 27% of ketamine responders had not relapsed by 4 weeks following a single ketamine infusion. The average time to relapse was 13.2 days (SE=2.2). However, the difference between the riluzole and placebo treatment groups was not significant, suggesting that the combination of riluzole with ketamine treatment did not significantly alter the course of antidepressant response to ketamine alone.

SUBMITTER: Ibrahim L 

PROVIDER: S-EPMC3327857 | biostudies-other | 2012 May

REPOSITORIES: biostudies-other

altmetric image

Publications

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.

Ibrahim Lobna L   Diazgranados Nancy N   Franco-Chaves Jose J   Brutsche Nancy N   Henter Ioline D ID   Kronstein Phillip P   Moaddel Ruin R   Wainer Irving I   Luckenbaugh David A DA   Manji Husseini K HK   Zarate Carlos A CA  

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120201 6


The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients with treatment-resistant major depression (TRD); these effects have been reported to last for 1 week in some patients. However, the extent and duration of this antidepressant effect over longer periods has not been well characterized under controlled conditions. Riluzole, a glutamatergic modulator with antidepressant and synaptic plasticity-enhancing effects, could conceivably be used to promote the antidep  ...[more]

Similar Datasets

| S-EPMC6587371 | biostudies-literature
| S-EPMC6447473 | biostudies-literature
| S-EPMC8329695 | biostudies-literature
| S-EPMC3335844 | biostudies-literature
| S-EPMC3606470 | biostudies-literature
| S-EPMC3816918 | biostudies-literature
| S-EPMC4224669 | biostudies-literature
| S-EPMC4186400 | biostudies-literature
| S-EPMC7428494 | biostudies-literature
| S-EPMC4163501 | biostudies-literature